Which medications in the drug class Molecular-targeted therapy are used in the treatment of Dermatofibrosarcoma Protuberans?

Updated: Mar 06, 2020
  • Author: Raman K Madan, MD; Chief Editor: William D James, MD  more...
  • Print

Molecular-targeted therapy

Before starting imatinib therapy, cytogenetic studies to confirm PDGFB gene rearrangement may be necessary for predicting the clinical response. Chromosome translocation t(17,22) is detected in more than 90% of DFSP tumors.

Imatinib mesylate (Gleevec)

Imatinib mesylate is an inhibitor of receptor tyrosine kinase for PDGF. It inhibits PDGF-B receptor-mediated cellular events, the key pathogenetic pathway in DFSP.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!